HIV Pre-Exposure Prophylaxis (PrEP) Linkage With Immediate Medications in the Emergency Department Study

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Texas Southwestern Medical Center

About this trial

Our primary objective is to increase HIV pre-exposure prophylaxis (PrEP) awareness and uptake among people who want, need, or would benefit from PrEP in Dallas, TX through a pilot program of immediate PrEP prescribing in the Parkland Memorial Hospital Emergency Department (ED) with linkage to PrEP clinic. Leveraging the previous work of the Parkland Center for Clinical Innovation (PCCI) which created an automated electronic health record (EHR) based HIV prediction tool and prior success with a robust ED HIV navigation program, a PrEP navigator would approach patients in the Parkland ED for PrEP initiation. Through standard care prescribing by their ED clinician, subjects would leave the ED with a prescription for rapid-start oral PrEP and a clinic appointment to persist on the PrEP modality of their choice which will include long-acting injectable options.

Eligibility criteria

Qualifiers

Able to comprehend and provide signed, written informed consent prior to initiation of study procedures.

Negative HIV rapid test

Requesting PrEP from their ED clinician

Score >75% on the PCCI HIV Prediction Tool

Disqualifiers

Known diagnosis of HIV

Positive HIV rapid test

Current use of PrEP, which is defined for purposes of this study as use of PrEP in the last 4 weeks

Known hypersensitivity or allergy to any PrEP modality

Trial design

Treatments tested in this trial

  • PrEP Uptake with Rapid Start
  • Pre-Exposure Prophylaxis (PrEP) Persistence

Treatment groups

250 Participants
are divided into 1 treatment group

Sponsors and collaborators